| Market Cap | 9.80K | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -12.53M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -100.00% |
| Sales | 15.45k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -100.00% |
| Dividend | N/A | Price/Book | 0.00 | EPS next 5Y | - | 52W High Chg | -100.00% |
| Recommedations | - | Quick Ratio | 0.00 | Shares Outstanding | 49M | 52W Low Chg | - |
| Insider Own | 57.95% | ROA | -558.67% | Shares Float | 23.35M | Beta | 1.19 |
| Inst Own | - | ROE | - | Shares Shorted/Prior | -/- | Price | 0.00020 |
| Gross Margin | 100.00% | Profit Margin | - | Avg. Volume | 8,593 | Target Price | - |
| Oper. Margin | -54,609.50% | Earnings Date | Apr 5 | Volume | 232 | Change | -98.73% |
Nanomix Corporation develops and commercializes mobile point-of-care diagnostic system that is used in performing a range of in vitro diagnostic tests in various environments. Its products are designed to enhance healthcare delivery by bringing diagnostic information to the point of initial patient interaction, whether in the hospital or in settings, such as nursing facilities, elderly homes, urgent care centers, airports, schools, and others. The company is also developing a pipeline of other tests designed to enhance patient outcomes by making diagnostic information available. Nanomix Corporation was founded in 2000 and is headquartered in San Leandro, California.
